Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics
about
Optical imaging of bacterial infectionsRising to the challenge: new therapies for tuberculosisMeropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosisDirected evolution of Mycobacterium tuberculosis β-lactamase reveals gatekeeper residue that regulates antibiotic resistance and catalytic efficiencyCan Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis -Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of -Lactam- -Lactamase Inhibitor CombinationsStructural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistanceKinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the β-Lactamase from Mycobacterium tuberculosisMorphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosisSaturation mutagenesis of Asn152 reveals a substrate selectivity switch in P99 cephalosporinaseNew Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in MycobacteriaImaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.The chemical biology of new drugs in the development for tuberculosis.Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probeBacterial growth and cell division: a mycobacterial perspective.Reporter enzyme fluorescence (REF) imaging and quantification of tuberculosis in live animalsCombinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.Fluorogenic probes with substitutions at the 2 and 7 positions of cephalosporin are highly BlaC-specific for rapid Mycobacterium tuberculosis detection.Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis InfectionHydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif.Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.Structural enzymology using X-ray free electron lasers.A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosisKinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognitionIn vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.Role of glycans and glycoproteins in disease development by Mycobacterium tuberculosis.Reappraising the use of β-lactams to treat tuberculosis.Molecular biology of drug resistance in Mycobacterium tuberculosisAntibiotic resistance mechanisms in M. tuberculosis: an update.β-Lactamase inhibition by avibactam in Mycobacterium abscessus.Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosisCeftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.New directions using reporter enzyme fluorescence (REF) as a tuberculosis diagnostic platform.
P2860
Q26747217-10F725EF-9926-414A-937C-B3E3914B9979Q27011672-817126D1-7F31-41F8-9871-A6C74C5D3870Q27653976-8DAAD214-6039-444C-9443-542A6F2F35D8Q27679915-16DDD15A-6032-4066-A80E-1D98694A1DA8Q27680025-BEB097B3-FA58-4A33-B723-D9890275B86AQ28084628-90EC53A0-495F-49AE-8E52-D0E0D4E51DCEQ28265806-F46A7F11-B653-4E7F-BC5C-CB5F4746F91CQ28487277-95E7F519-B9D5-4F35-BAE4-4277C26E4DE9Q33306655-37712EC2-24F5-4E4C-901C-F24C8044647FQ33600161-6BD61614-94F6-4080-9DE8-5FB2F5F5F74AQ33981892-DD269492-58E5-43F5-AE1B-930D4E103D9CQ34054325-16953EB2-79A7-4B64-A9D9-2688F3778345Q34060501-A41DEE1C-17B9-425D-8F57-04DD3D7E6885Q34655886-46DD5465-E67C-4A74-8A98-507D9CB83FD7Q34775748-6B37EEF5-2E2B-485C-8DC5-9948FC1B601EQ35236829-80AAFEF0-4E0C-449E-A9D6-85F22929094EQ35842780-265A131D-BFF5-44DE-ADF6-731D19BE2C76Q35860128-D39472EF-B5BE-43DF-A762-24FB7B2A789BQ35960711-068AE44D-3C22-4802-A487-ECCAECD57149Q36018749-DDF29D77-F26D-4672-8BEB-391AE5085844Q36248348-34898E7F-66ED-4A3C-B848-7BA372C8DC55Q36630989-006C67DB-D628-42DC-AF27-E0CC6A47AED8Q36804000-E1D65D62-580E-4EEB-A2DE-5C78B7F20FA7Q36957270-76D04023-5335-42BF-BB87-9135B81A9860Q37086328-2F039ED8-30C4-4889-B5E3-787EB35E64E5Q37112550-BF421505-9AE2-4D74-B935-BC2A6FC670AAQ37149906-737EEAD8-A121-4F61-A8CF-2C77D3B8E34EQ37255412-DB202C34-822A-496A-98EE-993BF779197EQ37335633-C8A5AE45-7788-4912-94F7-CAD363783DBDQ37983107-F5AF1933-ED2D-4C69-9F49-4AB789A2AA1AQ38056147-FF072488-534D-44A0-8E82-2C8395EEB47FQ38062402-348CF6E7-7F0C-4ADE-87E1-2549240E6094Q38830420-F0A645CA-3C68-4F93-AFFC-B0968AF9B642Q38927000-917D4224-2DAF-4AF9-8F58-DE258AA888C6Q39038482-13FE45EA-0C28-42AB-ABDE-F009EA39380DQ39765849-1526D376-121B-40BA-AF63-F3BA34CA0155Q40065397-931FC1A9-D1BB-47D4-BF5A-6AB1005B8A9DQ40187337-D924636D-BB36-431F-9AC0-23D1CC81592DQ40475389-E6DDC250-0B6F-4B00-9E7F-942BDD813584Q40510152-798C5634-C192-4012-91E1-17D4F2A5DCB9
P2860
Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics
description
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/08/01)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/08/01)
@nl
наукова стаття, опублікована в серпні 2006
@uk
مقالة علمية (نشرت في أغسطس 2006)
@ar
name
Crystal structure and activity ...... nce to beta-lactam antibiotics
@ast
Crystal structure and activity ...... nce to beta-lactam antibiotics
@en
Crystal structure and activity ...... nce to beta-lactam antibiotics
@nl
type
label
Crystal structure and activity ...... nce to beta-lactam antibiotics
@ast
Crystal structure and activity ...... nce to beta-lactam antibiotics
@en
Crystal structure and activity ...... nce to beta-lactam antibiotics
@nl
prefLabel
Crystal structure and activity ...... nce to beta-lactam antibiotics
@ast
Crystal structure and activity ...... nce to beta-lactam antibiotics
@en
Crystal structure and activity ...... nce to beta-lactam antibiotics
@nl
P2860
P921
P3181
P356
P1476
Crystal structure and activity ...... nce to beta-lactam antibiotics
@en
P2093
Craig Cassidy
James C. Sacchettini
P2860
P304
P3181
P356
10.1128/AAC.00320-06
P407
P50
P577
2006-08-01T00:00:00Z